Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $102.8 million.

  • Ironwood Pharmaceuticals' Net Income towards Common Stockholders rose 999.29% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 156.81%. This contributed to the annual value of $102.8 million for FY2024, which is 108.17% up from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Net Income towards Common Stockholders stood at $102.8 million, which was up 108.17% from -$1.3 billion recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $528.5 million in FY2021 and a low of -$1.3 billion during FY2023.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Net Income towards Common Stockholders value was $102.8 million (recorded in 2024), while the average stood at -$326.8 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Net Income towards Common Stockholders skyrocketed by 397.79% in 2021 and then slumped by 818.82% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at $106.2 million in 2020, then surged by 397.79% to $528.5 million in 2021, then slumped by 66.88% to $175.0 million in 2022, then slumped by 818.82% to -$1.3 billion in 2023, then surged by 108.17% to $102.8 million in 2024.